Drug shortage
Dexamethasone Sodium Phosphate Injection · Mylan Institutional, a Viatris Company
FDA drug shortage · Current · updated Apr 17, 2025
Key facts
| Generic name | Dexamethasone Sodium Phosphate Injection |
|---|---|
| Proprietary name | Dexamethasone Sodium Phosphate |
| Company | Mylan Institutional, a Viatris Company |
| Presentation | Dexamethasone Sodium Phosphate, Injection, 10 mg/1 mL (NDC 67457-420-10) |
| Dosage form | Injection |
| Strength | 10 mg/1 mL |
| Status | Current |
| Therapeutic category | Dermatology Endocrinology/Metabolism Gastroenterology Hematology Neurology Oncology Ophthalmology Other Pulmonary/Allergy Rheumatology |
| Package NDCs | 67457-420-10 |
| First posted | Feb 8, 2019 |
| Last updated | Apr 17, 2025 |
At a glance
- 1–9 Package NDCs affected
- 10–99 FDA shortage records for this drug
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA drug shortages
The FDA Drug Shortages Database lists current and resolved shortages of drugs, with presentations, affected NDCs and reasons reported by manufacturers.
Source: U.S. Food and Drug Administration (FDA), Drug Shortages Database · Source date: